

Index

- Acosta, M. *see* Iglesias, P.
 Agosti, B. *see* Cappelli, C.
 Akalin, S. *see* Yavuz, D.
 Akgul, E.O. *see* Ozcan, O.
 Akre, O. *see* Berinder, K.
 Alexiadis, M. *see* Fuller, P.J.
 Allemann, S. *see* Trepp, R.
 Al-Qahtani, A., Muttukrishna, S., Appasamy, M., Johns, J., Cranfield, M., Visser, J.A., Themmen, A.P.N. and Groome, N.P. Development of a sensitive enzyme immunoassay for anti-Müllerian hormone and the evaluation of potential clinical applications in males and females, 267
 Ambrosio, M.R. *see* Tita, P.
 Ammini, A.C. *see* Turton, J.P.G.
 Andria, G. *see* Melis, D.
 Appasamy, M. *see* Al-Qahtani, A.
 Arwert, L.I., Roos, J.C., Lips, P., Twisk, J.W.R., Manoliu, R.A. and Drent, M.L. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men, 310
 Asano, A. *see* Liang, H.
 Atkinson, A.B., Kennedy, A., Wiggam, M.I., McCance, D.R. and Sheridan, B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance, 549
 Auriemma, R.S. *see* Colao, A.
 Auriemma, R.S. *see* Vitale, G.
 Aversa, A. *see* Isidori, A.M.
 Aydin, T., Karacan, I., Demir, S.E. and Sahin, Z. Bone loss in males with ankylosing spondylitis: its relation to sex hormone levels, 467
 Baek, K.H. *see* Oh, K.W.
 Bähr, V. *see* Mai, K.
 Baik, S.H. *see* Kim, S.M.
 Baldazzi, L. *see* Nicoletti, A.
 Baldeschi, L. *see* Wakelkamp, I.M.M.J.
 Balsamo, A. *see* Nicoletti, A.
 Bana, N. *see* Brierley, J.
 Barbaro, D., Simi, U., Meucci, G., Lapi, P., Orsini, P. and Pasquini, C. Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers – are they different diseases?, 577
 Barbieri, M. *see* Rizzo, M.R.
 Barp, L. *see* Nicoletti, A.
 Barreca, A. *see* Resmini, E.
 Barrett, P.H.R. *see* Ng, T.W.K.
 Bartalena, L. *see* Bogazzi, F.
 Baxter, R.C. *see* Nelson, A.E.
 Beck-Peccoz, P. *see* Morpurgo, P.S.
 Bellastella, A. *see* De Bellis, A.
 Belloni, D.R. *see* Kinlaw, W.B.
 Benigno, V. *see* Melis, D.
 Berinder, K., Stackenäs, I., Akre, O., Hirschberg, A.L. and Hulting, A.-L. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up, 450
 Berioli, M.G. *see* Celi, F.
 Besser, G.M. *see* Chung, T.T.
 Betterle, C. *see* De Bellis, A.
 Beyhan, Z. *see* Ozcan, O.
 Biber, F.Z. *see* Darcan, S.
 Bilgi, C. *see* Ozcan, O.
 Bindu, G. *see* Stagi, S.
 Bini, V. *see* Celi, F.
 Biswas, M., Smith, J., Jadon, D., McEwan, P., Rees, D.A., Evans, L.M., Scanlon, M.F. and Davies, J.S. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas, 26
 Bizzarro, A. *see* De Bellis, A.
 Bobbert, T. *see* Mai, K.
 Bobbert, T., Brechtel, L., Mai, K., Otto, B., Maser-Gluth, C., Pfeiffer, A.F.H., Spranger, J. and Diederich, S. Adaptation of the hypothalamic-pituitary hormones during intensive endurance training, 530
 Boerlin, V. *see* van der Hoek, J.
 Bogazzi, F., Russo, D., Locci, M.T., Chifenti, B., Ultimieri, F., Raggi, F., Cosci, C., Sardella, C., Costa, A., Gasperi, M., Bartalena, L. and Martino, E. Apoptosis is reduced in the colonic mucosa of patients with acromegaly, 683
 Bolund, L. *see* Siggaard, C.
 Bona, G. *see* Camilot, M.
 Bondanelli, M. *see* Tita, P.
 Bonifacio, V. *see* Isidori, A.M.
 Bouloix, P.M. *see* Turton, J.P.G.
 Bowers, C.Y. *see* Soares-Welch, C.
 Bravata, D.M. *see* Liu, H.
 Brechtel, L. *see* Bobbert, T.
 Bremner, A.P. *see* Walsh, J.P.
 Brierley, J., Tsang, R., Panzarella, T. and Bana, N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years, 418
 Briganti, F. *see* Colao, A.
 Brismar, K. *see* Undén, A.-L.
 Broch, M. *see* González-Clemente, J.M.
 Broch, M. *see* Vilarrasa, N.
 Bronstein, M., Musolino, N., Jallad, R., Cendros, J.M., Ramis, J., Obach, R., Leselbaum, A. and Catus, F. Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days, 514
 Bronstein, M.D. *see* Jallad, R.S.
 Bulsara, M.K. *see* Walsh, J.P.
 Burlina, A.B. *see* Melis, D.
 Cabacan, J. *see* Liu, H.
 Cacciari, E. *see* Nicoletti, A.
 Caglieresi, C. *see* Canale, D.
 Caixàs, A. *see* González-Clemente, J.M.

Index

- Acosta, M. *see* Iglesias, P.
 Agosti, B. *see* Cappelli, C.
 Akalin, S. *see* Yavuz, D.
 Akgul, E.O. *see* Ozcan, O.
 Akre, O. *see* Berinder, K.
 Alexiadis, M. *see* Fuller, P.J.
 Allemann, S. *see* Trepp, R.
 Al-Qahtani, A., Muttukrishna, S., Appasamy, M., Johns, J., Cranfield, M., Visser, J.A., Themmen, A.P.N. and Groome, N.P. Development of a sensitive enzyme immunoassay for anti-Müllerian hormone and the evaluation of potential clinical applications in males and females, 267
 Ambrosio, M.R. *see* Tita, P.
 Ammini, A.C. *see* Turton, J.P.G.
 Andria, G. *see* Melis, D.
 Appasamy, M. *see* Al-Qahtani, A.
 Arwert, L.I., Roos, J.C., Lips, P., Twisk, J.W.R., Manoliu, R.A. and Drent, M.L. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men, 310
 Asano, A. *see* Liang, H.
 Atkinson, A.B., Kennedy, A., Wiggam, M.I., McCance, D.R. and Sheridan, B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance, 549
 Auriemma, R.S. *see* Colao, A.
 Auriemma, R.S. *see* Vitale, G.
 Aversa, A. *see* Isidori, A.M.
 Aydin, T., Karacan, I., Demir, S.E. and Sahin, Z. Bone loss in males with ankylosing spondylitis: its relation to sex hormone levels, 467
 Baek, K.H. *see* Oh, K.W.
 Bähr, V. *see* Mai, K.
 Baik, S.H. *see* Kim, S.M.
 Baldazzi, L. *see* Nicoletti, A.
 Baldeschi, L. *see* Wakelkamp, I.M.M.J.
 Balsamo, A. *see* Nicoletti, A.
 Bana, N. *see* Brierley, J.
 Barbaro, D., Simi, U., Meucci, G., Lapi, P., Orsini, P. and Pasquini, C. Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers – are they different diseases?, 577
 Barbieri, M. *see* Rizzo, M.R.
 Barp, L. *see* Nicoletti, A.
 Barreca, A. *see* Resmini, E.
 Barrett, P.H.R. *see* Ng, T.W.K.
 Bartalena, L. *see* Bogazzi, F.
 Baxter, R.C. *see* Nelson, A.E.
 Beck-Peccoz, P. *see* Morpurgo, P.S.
 Bellastella, A. *see* De Bellis, A.
 Belloni, D.R. *see* Kinlaw, W.B.
 Benigno, V. *see* Melis, D.
 Berinder, K., Stackenäs, I., Akre, O., Hirschberg, A.L. and Hulting, A.-L. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up, 450
 Berioli, M.G. *see* Celi, F.
 Besser, G.M. *see* Chung, T.T.
 Betterle, C. *see* De Bellis, A.
 Beyhan, Z. *see* Ozcan, O.
 Biber, F.Z. *see* Darcan, S.
 Bilgi, C. *see* Ozcan, O.
 Bindu, G. *see* Stagi, S.
 Bini, V. *see* Celi, F.
 Biswas, M., Smith, J., Jadon, D., McEwan, P., Rees, D.A., Evans, L.M., Scanlon, M.F. and Davies, J.S. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas, 26
 Bizzarro, A. *see* De Bellis, A.
 Bobbert, T. *see* Mai, K.
 Bobbert, T., Brechtel, L., Mai, K., Otto, B., Maser-Gluth, C., Pfeiffer, A.F.H., Spranger, J. and Diederich, S. Adaptation of the hypothalamic-pituitary hormones during intensive endurance training, 530
 Boerlin, V. *see* van der Hoek, J.
 Bogazzi, F., Russo, D., Locci, M.T., Chifenti, B., Ultimieri, F., Raggi, F., Cosci, C., Sardella, C., Costa, A., Gasperi, M., Bartalena, L. and Martino, E. Apoptosis is reduced in the colonic mucosa of patients with acromegaly, 683
 Bolund, L. *see* Siggaard, C.
 Bona, G. *see* Camilot, M.
 Bondanelli, M. *see* Tita, P.
 Bonifacio, V. *see* Isidori, A.M.
 Bouloix, P.M. *see* Turton, J.P.G.
 Bowers, C.Y. *see* Soares-Welch, C.
 Bravata, D.M. *see* Liu, H.
 Brechtel, L. *see* Bobbert, T.
 Bremner, A.P. *see* Walsh, J.P.
 Brierley, J., Tsang, R., Panzarella, T. and Bana, N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years, 418
 Briganti, F. *see* Colao, A.
 Brismar, K. *see* Undén, A.-L.
 Broch, M. *see* González-Clemente, J.M.
 Broch, M. *see* Vilarrasa, N.
 Bronstein, M., Musolino, N., Jallad, R., Cendros, J.M., Ramis, J., Obach, R., Leselbaum, A. and Catus, F. Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days, 514
 Bronstein, M.D. *see* Jallad, R.S.
 Bulsara, M.K. *see* Walsh, J.P.
 Burlina, A.B. *see* Melis, D.
 Cabacan, J. *see* Liu, H.
 Cacciari, E. *see* Nicoletti, A.
 Caglieresi, C. *see* Canale, D.
 Caixàs, A. *see* González-Clemente, J.M.

- Cakir, E. *see* Ozcan, O.
- Camilot, M., Teofoli, F., Gandini, A., Franceschi, R., Rapa, A., Corrias, A., Bona, G., Radetti, G. and Tatò, L. Thyrotropin receptor gene mutations and TSH resistance: variable expressivity in the heterozygotes, 146
- Canale, D., Caglieresi, C., Moschini, C., Liberati, C.D., Macchia, E., Pinchera, A. and Martino, E. Androgen receptor polymorphism (CAG repeats) and androgenicity, 356
- Capanna, R. *see* Mohn, A.
- Cappabianca, P. *see* Colao, A.
- Cappelli, C., Pirola, I., Cumetti, D., Micheletti, L., Tironi, A., Gandozzi, E., De Martino, E., Cherubini, L., Agosti, B., Castellano, M., Mattanza, C. and Rosei, E.A. Is the anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a sonographic criteria for recommending fine-needle aspiration cytology?, 689
- Cappiello, V. *see* Morpurgo, P.S.
- Carta, A. *see* Tita, P.
- Casa, R.D. *see* Melis, D.
- Cassar, J. *see* Turton, J.P.G.
- Castellano, M. *see* Cappelli, C.
- Caterina, G. *see* Palomba, S.
- Catus, F. *see* Bronstein, M.
- Celi, F., Bini, V., Papi, F., Santilli, E., Ferretti, A., Mencacci, M., Berioli, M.G., De Giorgi, G. and Falorni, A. Circulating acylated and total ghrelin and galanin in children with insulin-treated type 1 diabetes: relationship to insulin therapy, metabolic control and pubertal development, 139
- Cendros, J.M. *see* Bronstein, M.
- Chan, D.C.F. *see* Ng, T.W.K.
- Chan, I.H.S. *see* Ng, P.C.
- Channer, K.S. *see* Kapoor, D.
- Chen, Y.-J. *see* Liu, R.-T.
- Cheng, J.-T. *see* Liu, R.-T.
- Cherubini, L. *see* Cappelli, C.
- Chew, S.L. *see* Chung, T.T.
- Chiarelli, F. *see* Mohn, A.
- Chiarelli, F. *see* Stagi, S.
- Chifenti, B. *see* Bogazzi, F.
- Ching, H.L. *see* Ng, T.W.K.
- Cho, Y.M. *see* Kim, T.Y.
- Choi, D.S. *see* Kim, S.M.
- Choi, K.M. *see* Kim, S.M.
- Choi, M.G. *see* Oh, K.W.
- Chong, K. *see* Turton, J.P.G.
- Chou, F.-F. *see* Liu, R.-T.
- Christ, E.R. *see* Trepp, R.
- Christensen, J.H. *see* Siggaard, C.
- Christiansen, P. *see* Moosgaard, B.
- Chrousos, G.P. and Kaltsas, G. Post-SARS sickness syndrome manifestations and endocrinopathy: how, why, and so what?, 363
- Chung, T.T., Drake, W.M., Evanson, J., Walker, D., Plowman, P.N., Chew, S.L., Grossman, A.B., Besser, G.M. and Monson, J.P. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement, 274
- Chung, U.-I. *see* Lee, S.
- Cicognani, A. *see* Nicoletti, A.
- Cochran, E. *see* Musso, C.
- Coker, M. *see* Darcan, S.
- Colao, A. *see* Palomba, S.
- Colao, A. *see* Vitale, G.
- Colao, A., Pivonello, R., Cappabianca, P., Brigandt, F., Tortora, F., Auriemma, R.S., De Martino, M.C., Marzullo, P. and Lombardi, G. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly, 342
- Cole, D. *see* Soule, S.
- Cole, T.J. *see* Mehta, A.
- Conaglen, J.V. *see* Learoyd, D.L.
- Conte, M. *see* De Bellis, A.
- Copinschi, G. *see* Leproult, R.
- Coronella, C. *see* De Bellis, A.
- Corrias, A. *see* Camilot, M.
- Corydon, T.J. *see* Siggaard, C.
- Cosci, C. *see* Bogazzi, F.
- Costa, A. *see* Bogazzi, F.
- Cranfield, M. *see* Al-Qahtani, A.
- Crown, A. and Lightman, S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature, 483
- Cumetti, D. *see* Cappelli, C.
- D'Andrea, F. *see* Rizzo, M.R.
- Daniels, G.H. *see* Kinlaw, W.B.
- Darcan, S., Unak, P., Yalman, O., Lambrecht, F.Y., Biber, F.Z., Göksen, D. and Coker, M. Determination of iodine concentration in urine by isotope dilution analysis and thyroid volume of school children in the west coast of Turkey after mandatory salt iodization, 543
- Dattani, M.T. *see* Mehta, A.
- Dattani, M.T. *see* Turton, J.P.G.
- Dattani, M.T. Growth hormone deficiency and combined pituitary hormone deficiency: does the genotype matter?, 121
- Davies, J.H., Evans, B.A.J., Jenney, M.E.M. and Gregory, J.W. Skeletal morbidity in childhood acute lymphoblastic leukaemia, 1
- Davies, J.S. *see* Biswas, M.
- De Bellis, A., Bizzarro, A., Perrino, S., Coronella, C., Conte, M., Pasquali, D., Sinisi, A.A., Betterle, C. and Bellastella, A. Characterization of antipituitary antibodies targeting pituitary hormone-secreting cells in idiopathic growth hormone deficiency and autoimmune endocrine diseases, 45
- De Giorgi, G. *see* Celi, F.
- De Martino, E. *see* Cappelli, C.
- De Martino, M.C. *see* Colao, A.
- Deeb, A., Mason, C., Lee, Y.S. and Hughes, I.A. Correlation between genotype, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome, 56
- Deeg, D.J.H. *see* Puts, M.T.E.
- Delbridge, L.W. *see* Learoyd, D.L.
- Demir, S.E. *see* Aydin, T.
- Di Marzio D. *see* Mohn, A.
- Di Rocco, M. *see* Melis, D.
- Diederich, S. *see* Bobbert, T.
- Diederich, S. *see* Mai, K.
- Diez, J.J. *see* Iglesias, P.

- Donati, A. *see* Melis, D.
 Doyle, M.E. *see* Hardin, D.S.
 Drake, W.M. *see* Chung, T.T.
 Drent, M.L. *see* Arwert, L.I.
 Drop, S.L.S. *see* Mul, D.
 Dudczak, R. *see* Karanikas, G.
 Dunger, D.B. *see* Yuen, K.C.J.
 Dwivedi, M. *see* Sinha, S.
 Egle, U.T. *see* Kahaly, G.J.
 Elofsson, S. *see* Undén, A.-L.
 Elston, M.S. *see* Learoyd, D.L.
 Engelmann, M.D. *see* Øgard, C.G.
 Erbil, M.K. *see* Ozcan, O.
 Ernesti, M.M. *see* Kinlaw, W.B.
 Erturk, K. *see* Ozcan, O.
 Estepa, A. *see* Vilarrasa, N.
 Eunice, M. *see* Turton, J.P.G.
 Evans, B.A.J. *see* Davies, J.H.
 Evans, L.M. *see* Biswas, M.
 Evanson, J. *see* Chung, T.T.
 Everts, R. *see* Trepp, R.
 Fabbri, A. *see* Isidori, A.M.
 Falbo, A. *see* Palomba, S.
 Falorni, A. *see* Celi, F.
 Feddema, P. *see* Walsh, J.P.
 Feelders, R.A. *see* van der Hoek, J.
 Feldt-Rasmussen, U. *see* Klose, M.
 Fernández-Reyes, M.J. *see* Iglesias, P.
 Ferone, D. *see* Resmini, E.
 Ferraroni, N.R., Geloneze, B., Mansour, E., Perroud, A.P., Muscelli, E.O., Tambascia, M., de Lima Zollner, R. and Velloso, L.A. Severe hypoleptinaemia associated with insulin resistance in patients with common variable immunodeficiency, 63
 Ferretti, A. *see* Celi, F.
 Fischli, S. *see* Trepp, R.
 Fok, T.F. *see* Ng, P.C.
 Franceschi, R. *see* Camilot, M.
 Fryklund, L. *see* Yuen, K.C.J.
 Frystyk, J. *see* Yuen, K.C.J.
 Fuller, P.J., Alexiadis, M., Jobling, T. and McNeilage, J. Seladin-1/DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumours, 111
 Furlan, F. *see* Melis, D.
 Gómez, J.M. *see* Vilarrasa, N.
 Gøksen, D. *see* Darcan, S.
 Gandini, A. *see* Camilot, M.
 Gandossi, E. *see* Cappelli, C.
 Gangemi, P. *see* Tita, P.
 Gasperi, M. *see* Bogazzi, F.
 Gatti, R. *see* Melis, D.
 Geesey, M.E. *see* Hueston, W.J.
 Geloneze, B. *see* Ferraroni, N.R.
 Gennari, M. *see* Nicoletti, A.
 Gianfrilli, D. *see* Isidori, A.M.
 Giannetta, E. *see* Isidori, A.M.
 Giannini, C. *see* Mohn, A.
 Giménez-Pérez, G. *see* González-Clemente, J.M.
 Giménez-Palop, O. *see* González-Clemente, J.M.
 Giusti, M. *see* Resmini, E.
 Gong, G. *see* Kim, T.Y.
 González-Clemente, J.M., Mauricio, D., Richart, C., Broch, M., Caixàs, A., Megia, A., Giménez-Palop, O., Simón, I., Martínez-Riquelme, A., Giménez-Pérez, G. and Vendrell, J. Diabetic neuropathy is associated with activation of the TNF- α system in subjects with type 1 diabetes mellitus, 525
 Gooren, L.J.G. *see* Schaap, L.A.
 Gorden, P. *see* Musso, C.
 Gosnell, J. *see* Learoyd, D.L.
 Gozansky, W.S., Lynn, J.S., Laudenslager, M.L. and Kohrt, W.M. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic-pituitary-adrenal axis activity, 336
 Greco, E.A. *see* Isidori, A.M.
 Greenman, Y., Tordjman, K., Osher, E., Veshchev, I., Shenkerman, G., Reider-Groszasser, I.I., Segev, Y., Ouaknine, G. and Stern, N. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth, 39
 Gregersen, N. *see* Siggaard, C.
 Gregory, J.W. *see* Davies, J.H.
 Grella, E. *see* Rizzo, M.R.
 Grella, R. *see* Rizzo, M.R.
 Grobbee, D.E. *see* Lebrun, C.E.I.
 Groome, N.P. *see* Al-Qahtani, A.
 Grossman, A.B. *see* Chung, T.T.
 Guerra, E. *see* Vitale, G.
 Hana, V. *see* Silha, J.V.
 Handelsman, D.J. *see* Meier, C.
 Handelsman, D.J. *see* Nelson, A.E.
 Haq, M. and Harmer, C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome, 87
 Hardin, D.S., Rice, J., Doyle, M.E. and Pavia, A. Growth hormone improves protein catabolism and growth in prepubertal children with HIV infection, 259
 Hardt, J. *see* Kahaly, G.J.
 Harmer, C. *see* Haq, M.
 Harris, P.E. *see* Yuen, K.C.J.
 Harris, R.D. *see* Kinlaw, W.B.
 Heickendorff, L. *see* Moosgaard, B.
 de Herder, W.W. *see* van der Hoek, J.
 Hindmarsh, P.C. *see* Mehta, A.
 Hindmarsh, P.C. *see* Turton, J.P.G.
 Hirschberg, A.L. *see* Berinder, K.
 Hiura, Y. *see* Ueda, M.
 Ho, K.K. *see* Nelson, A.E.
 van der Hoek, J., van der Lelij, A.-J., Feelders, R.A., de Herder, W.W., Uitterlinden, P., Poon, K.W., Boerlin, V., Lewis, I., Krahneke, T., Hofland, L.J. and Lamberts, S.W. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients, 176
 Hofland, L.J. *see* van der Hoek, J.

- Hong, A.W.L. *see* Thomas, G.N.
 Hong, S.J. *see* Kim, T.Y.
 Howe, C.J. *see* Nelson, A.E.
 Huang, C.-C. *see* Liu, R.-T.
 Hueston, W.J., King, D.E. and Geesey, M.E. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism, 582
 Hughes, I.A. *see* Deeb, A.
 Hulting, A.-L. *see* Berinder, K.
 Hunt, P. *see* Soule, S.
 Hwang, R. *see* Lee, S.
 Idris, I., Srinivasan, R., Simm, A. and Page, R.C. Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome, 560
 Iglesias, P., Acosta, M., Sánchez, R., Fernández-Reyes, M.J., Mon, C. and Díez, J.J. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function, 66
 Ihm, S.H. *see* Oh, K.W.
 Inaba, M. *see* Ueda, M.
 Inder, W. *see* Soule, S.
 Ishikawa, T. *see* Ueda, M.
 Isidori, A. *see* Isidori, A.M.
 Isidori, A.M., Giannetta, E., Gianfrilli, D., Greco, E.A., Bonifacio, V., Versa, A., Isidori, A., Fabbri, A. and Lenzi, A. Effects of testosterone on sexual function in men: results of a meta-analysis, 381
 Isidori, A.M., Giannetta, E., Greco, E.A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A. and Fabbri, A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis, 280
 Jadon, D. *see* Biswas, M.
 Jagannathan, N.R. *see* Sinha, S.
 Jallad, R. *see* Bronstein, M.
 Jallad, R.S., Musolino, N.R.C., Salgado, L.R. and Bronstein, M.D. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution, 168
 Jarkovska, Z. *see* Silha, J.V.
 Javor, E.D. *see* Musso, C.
 Jenney, M.E.M. *see* Davies, J.H.
 Jenuso, R. *see* Stagi, S.
 Jezkova, J. *see* Silha, J.V.
 Jobling, T. *see* Fuller, P.J.
 Johns, J. *see* Al-Qahtani, A.
 Jones, T.H. *see* Kapoor, D.
 de Jong, F.H. *see* Lebrun, C.E.I.
 Kahaly, G.J., Petrak, F., Hardt, J., Pitz, S. and Egle, U.T. Psychosocial morbidity of Graves' orbitopathy, 395
 Kaltsas, G. *see* Chrousos, G.P.
 Kang, M.I. *see* Oh, K.W.
 Kapoor, D., Malkin, C.J., Channer, K.S. and Jones, T.H. Androgens, insulin resistance and vascular disease in men, 239
 Karacan, I. *see* Aydin, T.
 Karanikas, G., Schuetz, M., Wahl, K., Paul, M., Kontur, S., Piet-schmann, P., Kletter, K., Dudczak, R. and Willheim, M. Relation of anti-TPO autoantibody titre and T-lymphocyte cytokine production patterns in Hashimoto's thyroiditis, 191
 Katuta, Y. *see* Liang, H.
 Kaw, G.J.-L. *see* Leow, M.K.-S.
 Kazlauskas, R. *see* Nelson, A.E.
 Kennedy, A. *see* Atkinson, A.B.
 Kim, D.J. *see* Lee, S.
 Kim, H.Y. *see* Kim, S.M.
 Kim, N.H. *see* Kim, S.M.
 Kim, S.C. *see* Kim, T.Y.
 Kim, S.G. *see* Kim, S.M.
 Kim, S.M., Lee, J., Ryu, O.H., Lee, K.W., Kim, H.Y., Seo, J.A., Kim, S.G., Kim, N.H., Baik, S.H., Choi, D.S. and Choi, K.M. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity, 594
 Kim, S.Y. *see* Kim, T.Y.
 Kim, T.Y., Kim, W.B., Song, J.Y., Rhee, Y.S., Gong, G., Cho, Y.M., Kim, S.Y., Kim, S.C., Hong, S.J. and Shong, Y.K. The BRAF^{V600E} mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma, 588
 Kim, W.B. *see* Kim, T.Y.
 King, D.E. *see* Hueston, W.J.
 Kinlaw, W.B., Scott, S.M., Maue, R.A., Memoli, V.A., Harris, R.D., Daniels, G.H., Porter, D.M., Belloni, D.R., Spooner, E.T., Ernesti, M.M. and Noll, W.W. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma, 676
 Kistorp, C. *see* Øgard, C.G.
 Kletter, K. *see* Karanikas, G.
 Klose, M., Lange, M., Kosteljanetz, M., Poulsgaard, L. and Feldt-Rasmussen, U. Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test, 499
 Kobayashi, J. *see* Liang, H.
 Kohrt, W.M. *see* Gozansky, W.S.
 Kontur, S. *see* Karanikas, G.
 Koppeschaar, H.P.F. *see* Yuen, K.C.J.
 Kosteljanetz, M. *see* Klose, M.
 Krahnke, T. *see* van der Hoek, J.
 Krsek, M. *see* Silha, J.V.
 Kullmann, V. *see* Mai, K.
 Kumar, M. *see* Sinha, S.
 Kumar, V. *see* Sinha, S.
 Kumeda, Y. *see* Ueda, M.
 Kwek, D.S.-K. *see* Leow, M.K.-S.
 L'Hermite-Balériaux, M. *see* Leproult, R.
 Lam, C.W.K. *see* Ng, P.C.
 Lam, C.W.K. *see* Thomas, G.N.
 Lamberts, S.W. *see* van der Hoek, J.
 Lamberts, S.W.J. *see* Lebrun, C.E.I.
 Lambrecht, F.Y. *see* Darcan, S.
 Lange, M. *see* Klose, M.
 Lapi, E. *see* Stagi, S.
 Lapi, P. *see* Barbaro, D.
 Lau, E. *see* Thomas, G.N.
 Laudenslager, M.L. *see* Gozansky, W.S.
 Lauri, E. *see* Morpurgo, P.S.

- Lavis, V.R. *see* Picolos, M.K.
- Learoyd, D.L., Gosnell, J., Elston, M.S., Saurine, T.J., Richardson, A.-L., Delbridge, L.W., Conaglen, J.V. and Robinson, B.G. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations, 636
- Lebrun, C.E.I., van der Schouw, Y.T., de Jong, F.H., Pols, H.A.P., Grobbee, D.E. and Lamberts, S.W.J. Endogenous oestrogens are related to cognition in healthy elderly women, 50
- Lee, C.H. *see* Ng, P.C.
- Lee, J. *see* Kim, S.M.
- Lee, J. *see* Lee, S.
- Lee, K.W. *see* Kim, S.M.
- Lee, L.S.-U. *see* Leow, M.K.-S.
- Lee, S., Hwang, R., Lee, J., Rhee, Y., Kim, D.J., Chung, U.-I. and Lim, S.-K. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia, 625
- Lee, W.Y. *see* Oh, K.W.
- Lee, Y.S. *see* Deeb, A.
- Leedman, P.J. *see* Walsh, J.P.
- van der Lelij, A.-J. *see* van der Hoek, J.
- Lenzi, A. *see* Isidori, A.M.
- Leow, M.K.-S., Kwek, D.S.-K., Ng, A.W.-K., Ong, K.-C., Kaw, G.J.-L. and Lee, L.S.-U. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS), 197
- Leproult, R., Van Onderbergen, A., L'Hermite-Balériaux, M., Van Cauter, E. and Copinschi, G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men, 298
- Leselbaum, A. *see* Bronstein, M.
- Lewis, I. *see* van der Hoek, J.
- Li, C.-L. *see* Liu, R.-T.
- Liang, H., Murase, Y., Katuta, Y., Asano, A., Kobayashi, J. and Mabuchi, H. Association of LMNA 1908C/T polymorphism with cerebral vascular disease and diabetic nephropathy in Japanese men with type 2 diabetes, 317
- Liberati, C.D. *see* Canale, D.
- Lightman, S. *see* Crown, A.
- Lim, S.-K. *see* Lee, S.
- de Lima Zollner, R. *see* Ferraroni, N.R.
- Lips, P. *see* Arwert, L.I.
- Lips, P. *see* Puts, M.T.E.
- Lips, P. *see* Schaap, L.A.
- Liu, H., Bravata, D.M., Cabaccan, J., Raff, H. and Ryzen, E. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans, 642
- Liu, P.Y. *see* Meier, C.
- Liu, P.Y., Wang, C. and Swerdloff, R.S. Male sex matters, 601
- Liu, R.-T., Chen, Y.-J., Chou, F.-F., Li, C.-L., Wu, W.-L., Tsai, P.-C., Huang, C.-C. and Cheng, J.-T. No correlation between BRAF^{V600E} mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan, 461
- Locci, M.T. *see* Bogazzi, F.
- Lombardi, G. *see* Colao, A.
- Lombardi, G. *see* Vitale, G.
- Losi, S. *see* Stagi, S.
- Luthra, K. *see* Sinha, S.
- Lynn, J.S. *see* Gozansky, W.S.
- Möhlig, M. *see* Mai, K.
- Mabuchi, H. *see* Liang, H.
- Macchia, E. *see* Canale, D.
- Mai, K. *see* Bobbert, T.
- Mai, K., Kullmann, V., Bobbert, T., Maser-Gluth, C., Möhlig, M., Bähr, V., Pfeiffer, A.F.H., Spranger, J. and Diederich, S. *In vivo* activity of 11β-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance, 442
- Malkin, C.J. *see* Kapoor, D.
- Manguso, F. *see* Palomba, S.
- Manoliu, R.A. *see* Arwert, L.I.
- Mansour, E. *see* Ferraroni, N.R.
- Maravall, J. *see* Vilarrasa, N.
- Marcovecchio, M. *see* Mohn, A.
- Marek, J. *see* Silha, J.V.
- Martínez-Riquelme, A. *see* González-Clemente, J.M.
- Martino, E. *see* Bogazzi, F.
- Martino, E. *see* Canale, D.
- Martins, I.J. *see* Ng, T.W.K.
- Marzullo, P. *see* Colao, A.
- Maser-Gluth, C. *see* Bobbert, T.
- Maser-Gluth, C. *see* Mai, K.
- Mason, C. *see* Deeb, A.
- Mattanza, C. *see* Cappelli, C.
- Maue, R.A. *see* Kinlaw, W.B.
- Mauricio, D. *see* González-Clemente, J.M.
- McCance, D.R. *see* Atkinson, A.B.
- McEwan, P. *see* Biswas, M.
- McMillan, C.V. *see* Razvi, S.
- McNeilage, J. *see* Fuller, P.J.
- Megia, A. *see* González-Clemente, J.M.
- Megia, A. *see* Vilarrasa, N.
- Mehta, A. *see* Turton, J.P.G.
- Mehta, A., Hindmarsh, P.C., Stanhope, R.G., Turton, J.P.G., Cole, T.J., Preece, M.A. and Dattani, M.T. The role of growth hormone in determining birth size and early postnatal growth, using congenital growth hormone deficiency (GHD) as a model, 223
- Meier, C., Liu, P.Y., Handelman, D.J. and Seibel, M.J. Endocrine regulation of bone turnover in men, 603
- Melis, D., Parenti, G., Gatti, R., Casa, R.D., Parini, R., Riva, E., Burlina, A.B., Vici, C.D., Di Rocca, M., Furlan, F., Torcoletti, M., Papadia, F., Donati, A., Benigno, V. and Andria, G. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study, 19
- Melsen, F. *see* Moosgaard, B.
- Memoli, V.A. *see* Kinlaw, W.B.
- Mencacci, M. *see* Celi, F.
- Meucci, G. *see* Barbaro, D.
- Michelangeli, V. *see* Walsh, J.P.
- Micheletti, L. *see* Cappelli, C.
- Mielke, K.L. *see* Soares-Welch, C.
- Milone, F. *see* Vitale, G.

- Minuto, F. *see* Resmini, E.
- Misra, A. *see* Sinha, S.
- Mohn, A., Di Marzio, D., Giannini, C., Capanna, R., Marcovecchio, M. and Chiarelli, F. Alterations in the oxidant-antioxidant status in prepubertal children with growth hormone deficiency: effect of growth hormone replacement therapy, 537
- Mon, C. *see* Iglesias, P.
- Monson, J.P. *see* Chung, T.T.
- Moosgaard, B., Vestergaard, P., Heickendorff, L., Melsen, F., Christiansen, P. and Mosekilde, L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism, 506
- Morpurgo, P.S., Cappiello, V., Verga, U., Vicentini, L., Vaghi, I., Lauri, E., Nebuloni, M., Beck-Peccoz, P. and Spada, A. Ghrelin in human medullary thyroid carcinomas, 437
- Moschini, C. *see* Canale, D.
- Mosekilde, L. *see* Moosgaard, B.
- Mourits, M.P. *see* Wakelkamp, I.M.M.J.
- Mul, D., Oostdijk, W., Waelkens, J.J.J. and Drop, S.L.S. Final height after treatment of early puberty in short adopted girls with gonadotrophin releasing hormone agonist with or without growth hormone, 185
- Murase, Y. *see* Liang, H.
- Murgatroyd, P.R. *see* Yuen, K.C.J.
- Murphy, L.J. *see* Silha, J.V.
- Muscelli, E.O. *see* Ferraroni, N.R.
- Musolino, N. *see* Bronstein, M.
- Musolino, N.R.C. *see* Jallad, R.S.
- Musso, C., Shawker, T., Cochran, E., Javor, E.D., Young, J. and Gorden, P. Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth, 73
- Muttukrishna, S. *see* Al-Qahtani, A.
- Nagasaki, T. *see* Ueda, M.
- Nebuloni, M. *see* Morpurgo, P.S.
- Nelson, A.E., Howe, C.J., Nguyen, T.V., Seibel, M.J., Baxter, R.C., Handelman, D.J., Kazlauskas, R. and Ho, K.K. Erythropoietin administration does not influence the GH-IGF axis or makers of bone turnover in recreational athletes, 305
- Neri, A.S. *see* Stagi, S.
- Ng, A.W.-K. *see* Leow, M.K.-S.
- Ng, P.C., Lee, C.H., Lam, C.W.K., Chan, I.H.S., Wong, E. and Fok, T.F. Ghrelin in preterm and term newborns: relation to anthropometry, leptin and insulin, 217
- Ng, T.W.K., Watts, G.F., Stuckey, B.G.A., Ching, H.L., Chan, D.C.F., Uchida, Y., Sakai, N., Yamashita, S., Martins, I.J., Redgrave, T.G. and Barrett, P.H.R. Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?, 650
- Nguyen, T.V. *see* Nelson, A.E.
- Nicoletti, A., Baldazzi, L., Balsamo, A., Barp, L., Pirazzoli, P., Gennari, M., Radetti, G., Cacciari, E. and Cicognani, A. SRD5A2 gene analysis in an Italian population of under-masculinized 46,XY subjects, 475
- Nicoletti, G. *see* Rizzo, M.R.
- Nielsen, S.L. *see* Øgard, C.G.
- Nishizawa, Y. *see* Ueda, M.
- Noll, W.W. *see* Kinlaw, W.B.
- O'Leary, P. *see* Walsh, J.P.
- Obach, R. *see* Bronstein, M.
- Øgard, C.G., Engelmann, M.D., Kistorp, C., Nielsen, S.L. and Vestergaard, H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism, 493
- Oh, K.W., Lee, W.Y., Rhee, E.J., Baek, K.H., Yoon, K.H., Kang, M.I., Yun, E.J., Park, C.Y., Ihm, S.H., Choi, M.G., Yoo, H.J. and Park, S.W. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men, 131
- Ong, K.-C. *see* Leow, M.K.-S.
- Onoda, N. *see* Ueda, M.
- Oostdijk, W. *see* Mul, D.
- Orio Jr, F. *see* Palomba, S.
- Orlander, P.R. *see* Picolos, M.K.
- Orsini, P. *see* Barbaro, D.
- Osher, E. *see* Greenman, Y.
- Otto, B. *see* Bobbert, T.
- Ouaknine, G. *see* Greenman, Y.
- Ozcan, O., Cakir, E., Yaman, H., Akgul, E.O., Erturk, K., Beyhan, Z., Bilgi, C. and Erbil, M.K. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism, 203
- Özener, Ç. *see* Yavuz, D.
- Page, R.C. *see* Idris, I.
- Palomba, S., Orio Jr, F., Falbo, A., Russo, T., Caterina, G., Manguso, F., Tolino, A., Colao, A. and Zullo, F. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome, 631
- Pandey, R.M. *see* Sinha, S.
- Panzarella, T. *see* Brierley, J.
- Paolisso, G. *see* Rizzo, M.R.
- Papadia, F. *see* Melis, D.
- Papi, F. *see* Celi, F.
- Parenti, G. *see* Melis, D.
- Parini, R. *see* Melis, D.
- Park, C.Y. *see* Oh, K.W.
- Park, S.W. *see* Oh, K.W.
- Pasquali, D. *see* De Bellis, A.
- Pasquini, C. *see* Barbaro, D.
- Paul, M. *see* Karanikas, G.
- Pavia, A. *see* Hardin, D.S.
- Pedersen, E.B. *see* Sigaard, C.
- Pemberton, C. *see* Soule, S.
- Perrino, S. *see* De Bellis, A.
- Perroud, A.P. *see* Ferraroni, N.R.
- Petrak, F. *see* Kahaly, G.J.
- Pezzino, V. *see* Tita, P.
- Pfeiffer, A.F.H. *see* Bobbert, T.
- Pfeiffer, A.F.H. *see* Mai, K.
- Picolos, M.K., Lavis, V.R. and Orlander, P.R. Milk-alkali syndrome

- is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients, 566
- Pietschmann, P. *see* Karanikas, G.
- Pinchera, A. *see* Canale, D.
- Pirazzoli, P. *see* Nicoletti, A.
- Pirola, I. *see* Cappelli, C.
- Pitz, S. *see* Kahaly, G.J.
- Pivonello, R. *see* Colao, A.
- Pivonello, R. *see* Vitale, G.
- Plowman, P.N. *see* Chung, T.T.
- Pluijm, S.M.F. *see* Schaap, L.A.
- Pols, H.A.P. *see* Lebrun, C.E.I.
- Poon, K.W. *see* van der Hoek, J.
- Porter, D.M. *see* Kinlaw, W.B.
- Poulsgaard, L. *see* Klose, M.
- Preece, M.A. *see* Mehta, A.
- Prummel, M.F. *see* Wakelkamp, I.M.M.J.
- Puts, M.T.E., Visser, M., Twisk, J.W.R., Deeg, D.J.H. and Lips, P. Endocrine and inflammatory markers as predictors of frailty, 403
- Radetti, G. *see* Camilot, M.
- Radetti, G. *see* Nicoletti, A.
- Raff, H. *see* Liu, H.
- Raggi, F. *see* Bogazzi, F.
- Ragno, E. *see* Rizzo, M.R.
- Ramis, J. *see* Bronstein, M.
- Rapa, A. *see* Camilot, M.
- Rathi, M. *see* Sinha, S.
- Raudsep, S. *see* Soule, S.
- Raza, J. *see* Turton, J.P.G.
- Razvi, S., McMillan, C.V. and Weaver, J.U. Instruments used in measuring symptoms, health status and quality of life in hypothyroidism: a systematic qualitative review, 617
- Redgrave, T.G. *see* Ng, T.W.K.
- Rees, D.A. *see* Biswas, M.
- Reider-Groswasser, I.I. *see* Greenman, Y.
- Resmini, E., Barreca, A., Ferone, D., Giusti, M., Sidoti, M. and Minuto, F. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients, 294
- Reynolds, R.M. and Seckl, J.R. Hyponatraemia for the clinical endocrinologist, 366
- Rhee, E.J. *see* Oh, K.W.
- Rhee, Y. *see* Lee, S.
- Rhee, Y.S. *see* Kim, T.Y.
- Rice, J. *see* Hardin, D.S.
- Richardson, A.-L. *see* Learoyd, D.L.
- Richart, C. *see* González-Clemente, J.M.
- Richart, C. *see* Vilarrasa, N.
- Rittig, S. *see* Sigaard, C.
- Riva, E. *see* Melis, D.
- Rizzo, M.R., Paolisso, G., Grella, R., Barbieri, M., Grella, E., Ragni, E., Grella, R., Nicoletti, G. and D'andrea, F. Is dermolipectomy effective in improving insulin action and lowering inflammatory markers in obese women?, 253
- Robertson, G.L. *see* Sigaard, C.
- Robinson, B.G. *see* Learoyd, D.L.
- Roos, J.C. *see* Arwert, L.I.
- Rosei, E.A. *see* Cappelli, C.
- Rosicka, M. *see* Silha, J.V.
- Russo, D. *see* Bogazzi, F.
- Russo, T. *see* Palomba, S.
- Ryu, O.H. *see* Kim, S.M.
- Ryzen, E. *see* Liu, H.
- Saeed, P. *see* Wakelkamp, I.M.M.J.
- Sahin, Z. *see* Aydin, T.
- Sakai, N. *see* Ng, T.W.K.
- Salgado, L.R. *see* Jallad, R.S.
- Salvi, R. *see* Stagi, S.
- Sánchez, R. *see* Iglesias, P.
- Sanderson, J.E. *see* Thomas, G.N.
- Santilli, E. *see* Celi, F.
- Sardella, C. *see* Bogazzi, F.
- Saurine, T.J. *see* Learoyd, D.L.
- Savastano, S. *see* Vitale, G.
- Scanlon, M.F. *see* Biswas, M.
- Schaap, L.A., Pluijm, S.M.F., Smit, J.H., van Schoor, N.M., Visser, M., Gooren, L.J.G. and Lips, P. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women, 152
- van der Schouw, Y.T. *see* Lebrun, C.E.I.
- van Schoor, N.M. *see* Schaap, L.A.
- Schuetz, M. *see* Karanikas, G.
- Scollo, C. *see* Tita, P.
- Scott, S.M. *see* Kinlaw, W.B.
- Seckl, J.R. *see* Reynolds, R.M.
- Segev, Y. *see* Greenman, Y.
- Seibel, M.J. *see* Meier, C.
- Seibel, M.J. *see* Nelson, A.E.
- Seo, J.A. *see* Kim, S.M.
- Shawker, T. *see* Musso, C.
- Shenkerman, G. *see* Greenman, Y.
- Sheridan, B. *see* Atkinson, A.B.
- Shong, Y.K. *see* Kim, T.Y.
- Sidoti, M. *see* Resmini, E.
- Sigaard, C., Christensen, J.H., Corydon, T.J., Rittig, S., Robertson, G.L., Gregersen, N., Bolund, L. and Pedersen, E.B. Expression of three different mutations in the arginine vasopressin gene suggests genotype–phenotype correlation in familial neurohypophyseal diabetes insipidus kindreds, 207
- Silha, J.V., Krsek, M., Hana, V., Marek, J., Weiss, V., Jezkova, J., Rosicka, M., Jarkovska, Z. and Murphy, L.J. The effects of growth hormone status on circulating levels of vascular growth factors, 79
- Simón, I. *see* González-Clemente, J.M.
- Simón, I. *see* Vilarrasa, N.
- Simi, U. *see* Barbaro, D.
- Simm, A. *see* Idris, I.
- Sinha, S., Rathi, M., Misra, A., Kumar, V., Kumar, M., Jagannathan, N.R., Pandey, R.M., Dwivedi, M. and Luthra, K. Subclinical inflammation and soleus muscle intramyocellular lipids in healthy Asian Indian males, 350
- Sinisi, A.A. *see* De Bellis, A.

- Sirikçi, Ö. *see* Yavuz, D.
- Smit, J.H. *see* Schaap, L.A.
- Smith, J. *see* Biswas, M.
- Soares-Welch, C., Mielke, K.L., Bowers, C.Y. and Veldhuis, J.D. Short-term testosterone supplementation does not activate GH and IGF-I production in postmenopausal women, 32
- Soler, J. *see* Vilarrasa, N.
- Song, J.Y. *see* Kim, T.Y.
- Soule, S., Pemberton, C., Hunt, P., Cole, D., Raudsepp, S. and Inder, W. Prandial regulation of ghrelin secretion in humans: does glucagon contribute to the prandial increase in circulating ghrelin?, 412
- Spada, A. *see* Morpurgo, P.S.
- Spooner, E.T. *see* Kinlaw, W.B.
- Spranger, J. *see* Bobbert, T.
- Spranger, J. *see* Mai, K.
- Srinivasan, R. *see* Idris, I.
- Stackenäs, I. *see* Berinder, K.
- Stagi, S., Bindu, G., Neri, A.S., Lapi, E., Losi, S., Jenuso, R., Salti, R. and Chiarelli, F. Thyroid function and morphology in patients affected by Williams syndrome, 456
- Stanhope, R.G. *see* Mehta, A.
- Starzyk, J. *see* Turton, J.P.G.
- Stern, N. *see* Greenman, Y.
- Stettler, C. *see* Trepp, R.
- Stuckey, B.G.A. *see* Ng, T.W.K.
- Swerdloff, R.S. *see* Liu, P.Y.
- Tahara, H. *see* Ueda, M.
- Tambascia, M. *see* Ferraroni, N.R.
- Tatò, L. *see* Camilot, M.
- Teofoli, F. *see* Camilot, M.
- Themmen, A.P.N. *see* Al-Qahtani, A.
- Thomas, G.N., Hong, A.W.L., Tomlinson, B., Lau, E., Lam, C.W.K., Sanderson, J.E. and Woo, J. Effects of Tai Chi and resistance training on cardiovascular risk factors in elderly Chinese subjects: a 12-month longitudinal, randomized, controlled intervention study, 663
- Thomas, P.Q. *see* Turton, J.P.G.
- Tironi, A. *see* Cappelli, C.
- Tita, P., Ambrosio, M.R., Scollo, C., Carta, A., Gangemi, P., Bondanelli, M., Vigneri, R., Uberti, E.C.D. and Pezzino, V. High prevalence of differentiated thyroid carcinoma in acromegaly, 161
- Tiulpakov, A. *see* Turton, J.P.G.
- Tolino, A. *see* Palomba, S.
- Tomlinson, B. *see* Thomas, G.N.
- Topçu, G. *see* Yavuz, D.
- Torcoletti, M. *see* Melis, D.
- Tordjman, K. *see* Greenman, Y.
- Tortora, F. *see* Colao, A.
- Trepp, R., Everts, R., Stettler, C., Fischli, S., Allemann, S., Webb, S.M. and Christ, E.R. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL), 103, 238
- Tsai, P.-C. *see* Liu, R.-T.
- Tsang, R. *see* Brierley, J.
- Turton, J.P.G. *see* Mehta, A.
- Turton, J.P.G., Mehta, A., Raza, J., Woods, K.S., Tiulpakov, A., Cassar, J., Chong, K., Thomas, P.Q., Eunice, M., Ammini, A.C., Bouloux, P.M., Starzyk, J., Hindmarsh, P.C. and Dattani, M.T. Mutations within the transcription factor *PROPI* are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD), 10
- Twickler, T.B. *see* Yuen, K.C.J.
- Twisk, J.W.R. *see* Arwert, L.I.
- Twisk, J.W.R. *see* Puts, M.T.E.
- Uberti, E.C.D. *see* Tita, P.
- Uchida, Y. *see* Ng, T.W.K.
- Ueda, M., Inaba, M., Kumeda, Y., Nagasaki, T., Hiura, Y., Tahara, H., Onoda, N., Ishikawa, T. and Nishizawa, Y. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves' disease relapse, 657
- Uitterlinden, P. *see* van der Hoek, J.
- Ultimieri, F. *see* Bogazzi, F.
- Unak, P. *see* Darcan, S.
- Undén, A.-L., Elofsson, S. and Brismar, K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study, 94
- Vaghi, I. *see* Morpurgo, P.S.
- Van Cauter, E. *see* Leproult, R.
- Van Onderbergen, A. *see* Leproult, R.
- Veldhuis, J.D. *see* Soares-Welch, C.
- Velloso, L.A. *see* Ferraroni, N.R.
- Vendrell, J. *see* González-Clemente, J.M.
- Vendrell, J. *see* Vilarrasa, N.
- Verga, U. *see* Morpurgo, P.S.
- Veschev, I. *see* Greenman, Y.
- Vestergaard, H. *see* Øgard, C.G.
- Vestergaard, P. *see* Moosgaard, B.
- Vicentini, L. *see* Morpurgo, P.S.
- Vici, C.D. *see* Melis, D.
- Vigneri, R. *see* Tita, P.
- Vilarrasa, N., Vendrell, J., Maravall, J., Broch, M., Estepa, A., Megia, A., Soler, J., Simón, I., Richart, C. and Gómez, J.M. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population, 329
- Visser, J.A. *see* Al-Qahtani, A.
- Visser, M. *see* Puts, M.T.E.
- Visser, M. *see* Schaap, L.A.
- Vitale, G., Pivonello, R., Auriemma, R.S., Guerra, E., Milone, F., Savastano, S., Lombardi, G. and Colao, A. Hypertension in acromegaly and in the normal population: prevalence and determinants, 470
- Waelkens, J.J. *see* Mul, D.
- Wahl, K. *see* Karanikas, G.
- Wakelkamp, I.M.M.J., Baldeschi, L., Saeed, P., Mourits, M.P., Prummel, M.F. and Wiersinga, W.M. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial, 323
- Walker, D. *see* Chung, T.T.
- Walsh, J.P., Bremner, A.P., Bulsara, M.K., O'leary, P., Leedman, P.J., Feddema, P. and Michelangeli, V. Thyroid dysfunction and serum lipids: a community-based study, 670

- Wang, C. *see* Liu, P.Y.
Watts, G.F. *see* Ng, T.W.K.
Weaver, J.U. *see* Razvi, S.
Weaver, J.U. Obesity, cytokines and the search for beauty, 251
Webb, S.M. *see* Trepp, R.
Weiss, V. *see* Silha, J.V.
White, D.K. *see* Yuen, K.C.J.
Wiersinga, W.M. *see* Wakelkamp, I.M.M.J.
Wiggam, M.I. *see* Atkinson, A.B.
Willheim, M. *see* Karanikas, G.
Wong, E. *see* Ng, P.C.
Woo, J. *see* Thomas, G.N.
Woods, K.S. *see* Turton, J.P.G.
Wu, W.-L. *see* Liu, R.-T.
Xing, M.Z. The T1799A *BRAF* mutation is not a germline mutation in familial nonmedullary thyroid cancer, 263
Yalman, O. *see* Darcan, S.
Yaman, H. *see* Ozcan, O.
Yamashita, S. *see* Ng, T.W.K.
Yavuz, D., Topçu, G., Özener, Ç., Akalın, S. and Sirikçi, Ö. Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy, 520
Yoo, H.J. *see* Oh, K.W.
Yoon, K.H. *see* Oh, K.W.
Young, J. *see* Musso, C.
Yuen, K.C.J., Frystyk, J., White, D.K., Twickler, T.B., Koppeschaar, H.P.F., Harris, P.E., Fryklund, L., Murgatroyd, P.R. and Dunger, D.B. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency, 428
Yun, E.J. *see* Oh, K.W.
Zullo, F. *see* Palomba, S.

Subject index to Volume 63

- ACE-inhibitor therapy
renal disease in GSD1 19
- Acromegaly
cabergoline and somatostatin analogues (Letter) 477
differentiated thyroid carcinoma 161
effects of therapy on GH secretion 294
GH status and vascular growth factors 79
hypertension in 470
long-term somatostatin analogue therapy 342
octreotide therapy 168, 176, 342
pharmacokinetic profile of lanreotide Autogel® 514
quality of life questionnaire 103
reduced apoptosis in colonic mucosa 682
- AcroQoL questionnaire for acromegaly 103
- ACTH
familial ACTH-independent macronodular adrenal hyperplasia 624
in Nelson's syndrome and Cushing's disease (Letter) 232
- Addison's disease
in hyponatraemia (Review) 368
- Adiponectin
BMD in men 131
in regulation of body composition 329
- Adiposity
ghrelin and galanin in children with IDDM 139
ADMA (asymmetric dimethylarginine)
thyroxine replacement and cardiovascular risk 203
- Adrenal hyperplasia
familial ACTH-independent macronodular 624
- Adrenal insufficiency (primary and secondary)
in hyponatraemia (Review) 368
- Adrenocortical insufficiency
role of synacthen test 499
- Age
androgens, insulin resistance and vascular disease in men (Review) 241
effects of testosterone in middle-aged men 280
endocrine regulation of bone turnover in men (Review) 604
regulation of body composition 329
see also Elderly subjects
- Agomelatine
phase-shifting effects in older men 298
- ALL
childhood, skeletal morbidity (Review) 1
- Anabolic steroids
androgens, insulin resistance and vascular disease in men (Review) 244
- Androgenicity
androgen receptor polymorphism 356
- Androgens
insulin resistance and vascular disease in men (Review), 239
partial androgen insensitivity syndrome 56
- Ankylosing spondylitis
bone loss in men 467
- Anthropometry
ghrelin in preterm and term newborns 217
- Anti-Müllerian hormone
development and evaluation of assay 267
- Antipituitary antibodies
in GHD and autoimmune endocrine diseases 45
- Apoptosis
reduced, in acromegalic colon mucosa 682
- Arginine vasopressin (AVP)
genotype-phenotype correlation in diabetes insipidus 207
- Atherosclerosis
arterial stiffness and osteoprotegerin 594
in primary hyperparathyroidism 493
- Athletes
adaptation of HPA axis during endurance training 530
erythropoietin administration 305
- Autoantibodies
in Hashimoto's thyroiditis 191
- Autoimmune diseases
antipituitary antibodies 45
- Blood pressure
ambulatory monitoring and thyroid function 66
- Body composition
adiponectin, resistin and ghrelin in regulation 329
effects of low-dose GH in severe GHD 428
effects of testosterone in middle-aged men 280
long-term effects of GH therapy 31
- Bone
BMD, and adipocytokines in men 131
BMD, long-term effects of GH therapy 31
BMD, in primary hyperparathyroidism 506
endocrine regulation of turnover in men (Review) 602
loss, in ankylosing spondylitis 467
in management of glucocorticoid deficiency (Review) 486
metabolism, in childhood ALL (Review) 1
metabolism, effects of testosterone in middle-aged men, 280
metabolism, and erythropoietin administration in athletes 305
- Bromocriptine
withdrawal of therapy for microprolactinomas 26
- Cabergoline
in acromegaly (Letter) 477
withdrawal of therapy for microprolactinomas 26
- Calcitonic hormones
in regulation of bone turnover in men (Review) 608
- Calcium
arterial stimulation in insulinoma localization (Letter) 480
- Cardiovascular risk
androgens and insulin resistance in men (Review) 239

- effects of Tai Chi and resistance training 662
- effects of thyroxine replacement 203
- gender and IGFBP-1 94
- GHD and type 2 diabetes (Letter) 700
- LMNA 1908C/T polymorphism in type 2 diabetes 317
- low-dose GH in severe GHD 428
- management of glucocorticoid deficiency (Review) 488
- osteoprotegerin levels 594
- in primary hyperparathyroidism 493
- in subclinical hypothyroidism 582
- Cerebral vascular disease
 - LMNA 1908C/T polymorphism in type 2 diabetes 317
- Chemotherapy
 - in childhood ALL (Review) 1
- Children
 - alterations in oxidant-antioxidant status in GHD 537
 - evaluation of iodine deficiency status 543
 - GH, growth and protein catabolism in HIV infection 259
 - ghrelin and galanin in type 1 diabetes mellitus 139
 - sex of rearing and PAIS 56
 - skeletal morbidity in ALL (Review) 1
 - treatment of early puberty in girls 185
- Chylomicron
 - remnant catabolism in type 2 diabetes 649
- Circadian rhythm
 - phase-shifts in older men 298
- Clomiphene citrate
 - in ovulation induction in PCOS 630
- Cognition
 - oestrogens in elderly women 50
- Colon mucosa
 - reduced apoptosis in acromegaly 682
- Cortisol
 - management of glucocorticoid deficiency (Review) 484
 - salivary, assay of HPA axis activity 336
 - salivary, effects of lemon juice on assays (Letter) 478
 - salivary, elevated in type 2 diabetes 641
- Cortisone
 - management of glucocorticoid deficiency (Review) 484
- CPHD (combined pituitary hormone deficiency)
 - genetic factors 10, (Review) 121
- C-reactive protein (CRP)
 - as predictor of frailty 403
 - soleus muscle IMCL and insulin sensitivity 350
 - in subclinical hypothyroidism 582
- CT (computed tomography)
 - surveillance imaging for extrapituitary tumours 274
- Cushing's disease/syndrome
 - ACTH secretory process (Letter) 232
 - familial ACTH-independent macronodular adrenal hyperplasia 624
 - long-term remission rates post-surgery 549
 - long-term rosiglitazone (Letter) 118
 - with tuberous sclerosis (Letter) 693
- Cytokines
 - in Hashimoto's thyroiditis 191
- IL-13 and chromosome studies in Graves' disease 695
- response following dermolipectomy 253,
 - (Commentary) 251
- TNF- α in diabetic neuropathy 525
- Dermolipectomy
 - insulin action and inflammatory markers 253, (Commentary) 251
- DHEA
 - androgens, insulin resistance and vascular disease in men (Review) 245
- Diabetes insipidus
 - AVP gene 207
 - extrapontine myelinolysis and acute severe hypernatraemia (Letter) 233
- Diabetes mellitus
 - ghrelin and galanin in IDDM in children 139
 - osteoprotegerin and cardiovascular risk 594
 - type 1, and diabetic neuropathy 525
 - type 2, androgens, insulin resistance and vascular disease in men (Review) 239
 - type 2, elevated salivary cortisol in elderly males 641
 - type 2, GHD and vascular complications (Letter) 700
 - type 2, LMNA 1908C/T polymorphism 317
 - type 2, statins and chylomicron remnant catabolism 649
 - type 2, subclinical hypothyroidism in women (Letter) 479
- Dialysis patients
 - erythropoietin administration in athletes 305
- Dietary factors
 - in childhood ALL (Review) 1
- Dopamine agonist therapy
 - nonfunctioning pituitary adenomas 39
 - withdrawal and microprolactinomas 26
- Doping tests
 - erythropoietin administration in athletes 305
- EIA (enzyme immunoassay)
 - salivary cortisol and HPA axis activity 336
- Elderly subjects
 - agomelatine and phase-shifting in men 298
 - elevated salivary cortisol in type 2 diabetes 641
 - oestrogens and cognition in women 50
 - predictors of frailty 403
 - sex hormones, mobility and muscle strength 152
 - Tai Chi, resistance training and cardiovascular risk 662
- ELISA
 - for anti-Müllerian hormone 267
- Endocrinopathy
 - following SARS 197, (Commentary) 363
- Endurance training
 - adaptation of HPA axis 530
- Erectile function
 - effects of testosterone 381, (Commentary) 600
- Erythropoietin
 - administration in athletes 305

Exercise

- endurance training and adaptation of HPA axis 530
- Tai Chi, resistance training and cardiovascular risk 662

Falls

- sex hormones and gender in the elderly 152

Fine-needle aspiration cytology

- nonpalpable thyroid nodules 688

Frailty

- endocrine and inflammatory markers as predictors 403

Free fatty acids (FFAs)

- 11B-HSD1 activity 442

Galanin

- in children with IDDM 139

Gender

- cardiovascular risk and IGFBP-1 94

see also Men; Women

Genetics

- androgen receptor polymorphism and androgenicity 356
- BRAF^{V600E}* mutation in papillary thyroid carcinomas 461, 588
- combined pituitary hormone deficiency 10, (Review) 121
- differential diagnosis of under-masculinization 375
- familial AIMAH and expression of vasopressin receptors 624
- familial nonmedullary thyroid cancer and T1799A *BRAF* mutation 263
- genotype-phenotype correlation in diabetes insipidus 207
- GHD (Review) 121
- GHD, type 2 diabetes and vascular complications (Letter) 700
- IL-13 and chromosome studies in Graves' disease 695
- LMNA 1908C/T polymorphism in type 2 diabetes 317
- partial androgen insensitivity syndrome 56
- prophylactic thyroidectomy in MEN 2A kindreds 635
- seladin-1 expression in ovarian tissue 111
- susceptibility loci for Graves' disease (Letter) 232
- TSH receptor and TSH resistance 146
- unique MEN type 2A phenotype 675

GH

- axis, and erythropoietin administration in athletes 305
- effects on birth size and early growth 223
- effects of therapeutic modalities in acromegaly 294
- growth and protein catabolism in HIV-infected children 259
- low-dose, in severe GHD 428
- prandial regulation 412
- status and vascular growth factors 79
- surveillance imaging for extrapituitary tumours 274
- testosterone supplementation in postmenopausal women 32
- therapy, long-term effects in men 310
- treatment of early puberty in girls 185

GHD

- alterations in oxidant-antioxidant status 537
- antipituitary antibodies 45
- congenital, effects on birth size and early growth 223

effects of low-dose GH 428

- effects on vascular growth factors 79

genetic factors (Review) 121

type 2 diabetes and vascular complications (Letter) 700

Ghrelin

- BMD in men 131
- in children with IDDM 139
- in medullary thyroid carcinoma 437
- prandial regulation 412
- in preterm and term newborns 217
- in regulation of body composition 329

Gitelman's syndrome

- in late adulthood (Letter) 697

Glucagon

- in prandial regulation of ghrelin 412

Glucocorticoid

- in childhood ALL (Review) 1
- management of deficiency (Review) 483
- insufficiency in hyponatraemia (Review) 368

Glycogen storage disease

- type 1, ACE-inhibitor therapy 19

Gonadotrophin releasing hormone agonist

- treatment of early puberty in girls 185

Gonadotropins

- ovarian growth and hyperinsulinaemia 73

Graves' disease

- IL-13 and chromosome studies 695
- optic neuropathy in ophthalmopathy 323
- psychosocial morbidity of orbitopathy 395
- relapse, and thyroid blood flow 656
- susceptibility loci (Letter) 232

Hashimoto's thyroiditis

- TPOAb and T-lymphocyte cytokines 191

Height

- after treatment of early puberty in girls 185
- GH therapy in HIV-infected children 259

HIV infection

- GH, growth and protein catabolism in children 259

Homocysteine

- in subclinical hypothyroidism 582
- HPA (hypothalamo-pituitary-adrenal) axis
- adaptation in endurance training 530
- following SARS 197, (Commentary) 363
- reliability of synacthen test 499
- salivary cortisol assay 336

 11β -Hydroxysteroid dehydrogenase

- adaptation of HPA axis during endurance training 530
- management of glucocorticoid deficiency (Review) 484
- type 1, in insulin resistance 442

25-Hydroxyvitamin D

- in primary hyperparathyroidism 506

Hypercalcaemia

- milk-alkali syndrome and renal disease 566

Hypercholesterolaemia

- in subclinical hypothyroidism 669

- Hypercortisolism
 following SARS 197, (Commentary) 363
 post-surgery for Cushing's disease 549
- Hyperglycaemia
 in hyponatraemia (Review) 367
- Hyperinsulinaemia
 ovarian growth and gonadotropins 73
- Hypernatraemia
 acute severe, extrapontine myelinolysis and diabetes insipidus (Letter) 233
- Hyperparathyroidism, primary
 cardiovascular risk markers 493
 vitamin D status 506
- Hyperprolactinaemia
 in chronic renal failure 520
 clinical follow-up in women 450
- Hypertension
 in acromegaly and normal population 470
- Hyperthyroidism
 ambulatory blood pressure monitoring 66
- Hypoadrenalinism
 management of glucocorticoid deficiency (Review) 483
- Hypoandrogenism
 androgen receptor polymorphism 356
- Hypogonadism
 androgens, insulin resistance and vascular disease in men (Review) 240, 245
 long-term somatostatin analogue therapy 342
- Hypokalaemia
 Gitelman's syndrome in late adulthood (Letter) 697
- Hypolectinaemia
 in common variable immunodeficiency syndrome 63
- Hypomagnesaemia
 Gitelman's syndrome in late adulthood (Letter) 697
- Hyponatraemia
 pathophysiology, diagnosis and management (Review) 366
- Hypopituitarism
 genetic factors (Review) 121
 in hyponatraemia (Review) 368
PROPI mutations in CPHD 10
 with xanthoma disseminatum (Letter) 119
- Hypothalamo-pituitary axis
 development (Review) 121
- Hypothyroidism
 automated thyroid register (Letter) 116
 in early and late gestation 560
 evaluation of symptoms and quality of life 616
 subclinical, in diabetes mellitus type 2 (Letter) 479
 subclinical, markers for cardiovascular inflammation 582
 subclinical, and serum lipids 669
 thyroxine replacement and cardiovascular risk 203
 TSH receptor gene mutations and resistance 146
- IGFBP-1
 gender and cardiovascular risk factors 94
- IGF-I
 erythropoietin administration in athletes 305
 gender and cardiovascular risk factors 94
 hypertension in acromegaly and normal population 470
 low-dose GH in severe GHD 428
 as predictor of frailty 403
 in regulation of body composition 329
 testosterone supplementation in postmenopausal women 32
- Immunodeficiency
 common variable immunodeficiency syndrome 63
- Infertility
 androgen receptor polymorphism and androgenicity 356
 assay for anti-Müllerian hormone 267
- Inflammatory markers
 C-reactive protein and insulin resistance 350
 following dermoliposcopy 253, (Commentary) 251
 osteoprotegerin and cardiovascular risk 594
 as predictors of frailty 403
 in primary hyperparathyroidism 493
 in subclinical hypothyroidism 582
- Instruments
 quality of life and health status in hypothyroidism 616
- Insulin
 action following dermoliposcopy 253, (Commentary) 251
 ghrelin and galanin in IDDM in children 139
 ghrelin in preterm and term newborns 217
 resistance, 11 β -hydroxysteroid dehydrogenase type 1 activity 442
 resistance, androgens and vascular disease in men (Review) 239
 resistance, in common variable immunodeficiency syndrome 63
 sensitivity, and low-dose GH in severe GHD 428
 sensitivity, subclinical inflammation and soleus muscle IMCL 350
- Insulinoma
 localization (Letter) 480
- Interleukins
 IL-6, as predictor of frailty 403
 IL-13, chromosome studies in Graves' disease 695
- Iodine deficiency
 evaluation of status in children 543
- Lanreotide
 Autogel®, pharmacokinetic profile in acromegaly 514
 long-term treatment of acromegaly 342
- Leptin
 BMD in men 131
 in common variable immunodeficiency syndrome 63
 ghrelin in preterm and term newborns 217
- Leukaemia, acute lymphoblastic see ALL
- Lipids
 effects of testosterone in middle-aged men 280
 long-term effects of GH therapy 31
 soleus muscle intramyocellular 350
 in subclinical hypothyroidism 669

- Macroprolactin
 in renal replacement therapy 520
- Masculinization
 differential diagnosis of under-masculinization 375
 partial androgen insensitivity syndrome 56
- Melatonin
 phase-shifting effects in older men 298
- Men
 adipocytokines and BMD 131
 agomelatine and phase-shifting 298
 androgens, insulin resistance and vascular disease (Review) 239
 bone loss in ankylosing spondylitis 467
 effects of testosterone on sexual function 381, (Commentary) 600
 elderly, elevated salivary cortisol in type 2 diabetes, 641
 endocrine regulation of bone turnover (Review) 602
 infertility, assay for anti-Müllerian hormone 267
 long-term effects of GH therapy 31
 long-term somatostatin analogue therapy 342
 middle-aged, effects of testosterone 280
 regulation of body composition 329
 sex hormones, mobility and muscle strength in the elderly 152
- Metabolic syndrome
 androgens, insulin resistance and vascular disease in men (Review) 239
- Metabolism
 ghrelin and galanin in type 1 diabetes mellitus 139
- Metformin
 in ovulation induction in PCOS 630
- Methylprednisolone
 for optic neuropathy in Graves' ophthalmopathy 323
- Microprolactinoma
 withdrawal of dopamine agonist therapy 26
- Milk-alkali syndrome
 renal disease and hypercalcaemia 566
- Mineral homeostasis
 in childhood ALL (Review) 1
- Mobility
 sex hormones and gender in the elderly 152
- MRI (magnetic resonance imaging)
 surveillance imaging for extrapituitary tumours 274
- Multiple endocrine neoplasia (MEN), type 2A
 prophylactic thyroidectomy in kindreds 635
 unique phenotype 675
- Muscle strength
 sex hormones and gender in the elderly 152
- Myelinolysis, extrapontine
 diabetes insipidus and acute severe hypernatraemia (Letter) 233
- Natriuretic peptide
 in primary hyperparathyroidism 493
- Nelson's syndrome
 ACTH secretory process (Letter) 232
- Neonates
 effects of GH on birth size and early growth 223
 maternal hypothyroidism in gestation 560
 preterm and term, and ghrelin 217
- Nephropathy
 GHD and type 2 diabetes (Letter) 700
 LMNA 1908C/T polymorphism in type 2 diabetes 317
- Obesity
 androgens, insulin resistance and vascular disease in men (Review) 242, 245
 dermolipectomy, insulin action and inflammatory markers 253, (Commentary) 251
 soleus muscle IMCL 350
- Octreotide therapy
 in acromegaly 168, 176, 342
- Oestrogens
 cognition in elderly women 50
- Optic neuropathy
 treatment in Graves' ophthalmopathy 323
- Orbitopathy, Graves'
 psychosocial morbidity 395
- Osteopenia
 in childhood ALL (Review) 1
- Ovarian function
 assay for anti-Müllerian hormone 267
 enlargement and hyperinsulinaemia 73
 ovulation induction 630
 seladin-1 expression 111
- Ovarian tumours
 epithelial and granuloma cell 111
- Oxidant-antioxidant status
 alterations in children with GHD 537
- Parathyroid adenoma
 weight, in primary hyperparathyroidism 506
- Phase-shifts
 effects of agomelatine in older men 298
- Pheochromocytoma
 unique MEN type 2A phenotype 675
- Pituitary adenomas
 dopamine agonist therapy 39
- Pituitary disease
 combined pituitary hormone deficiency 10, (Review) 121
 GHD and antipituitary antibodies 45
- Polycystic ovary syndrome (PCOS)
 ovulation induction 630
- Pravastatin
 type 2 diabetes, statins and chylomicron remnant catabolism 649
- Pregnancy
 hypothyroidism in 560
 management of glucocorticoid deficiency (Review) 484, 489
- Prolactin
 in renal replacement therapy 520

- Protein
 catabolism in HIV-infected children 259
- Pseudohyponatraemia
 in diagnosis of hyponatraemia (Review) 367
- Psychosocial factors
 morbidity of Graves' orbitopathy 395
- PTH
 in regulation of bone turnover in men (Review) 608
- Puberty
 early, height after treatment 185
 ghrelin and galanin in type 1 diabetes mellitus 139
- Quality of life
 AcroQoL questionnaire for acromegaly 103
 in hypothyroidism 616
 management of glucocorticoid deficiency (Review) 488
 psychosocial morbidity of Graves' orbitopathy 395
- Radiation therapy
 external beam, and differentiated thyroid cancer 418
 GH secretion in acromegaly 294
- Radioactive iodine
 for differentiated thyroid cancer 418
- Renal disease
 ACE-inhibitor therapy in GSD1 19
 diabetic nephropathy and LMNA 1908C/T polymorphism 317
 hyperprolactinaemia in chronic renal failure 520
 milk-alkali syndrome and hypercalcaemia 566
 nephropathy, GHD and type 2 diabetes (Letter) 700
- Resistin
 BMD in men 131
 in regulation of body composition 329
- Retinopathy
 GHD and type 2 diabetes (Letter) 700
- Rosiglitazone
 long-term, in Cushing's disease (Letter) 118
- SARS (severe acute respiratory syndrome)
 endocrine sequelae 197, (Commentary) 363
- Seladin-1
 expression in ovarian tissue and tumours 111
- Septo-optic dysplasia
 genetic factors (Review) 121
- Sex hormones
 bone loss in ankylosing spondylitis in men 467
 mobility and muscle strength in the elderly 152
 in regulation of bone turnover in men (Review) 605
- Sexual function
 effects of testosterone in men 381, (Commentary) 600
- SHBG
 androgens, insulin resistance and vascular disease in men (Review) 242
- Short stature
 treatment of early puberty in girls 185
- Skeletal morbidity, in childhood ALL (Review) 1
- Soleus muscle
 IMCL, subclinical inflammation and insulin sensitivity 350
- Somatostatin analogues
 in acromegaly 168, 176, (Letter) 477, 342, 514
 pharmacokinetic profile of lanreotide Autogel® 514
- Sonography
 nonpalpable thyroid nodules 688
- Steroids
 for optic neuropathy in Graves' ophthalmopathy 323
- Surveillance imaging
 GH therapy and extrapituitary tumours 274
- Synacthen test
 audit of reliability 499
- Tai Chi
 effects on cardiovascular risk factors 662
- Testosterone
 effects on sexual function in men 381, (Commentary) 600
 insulin resistance and vascular disease in men (Review) 239
 measurement in men (Review) 239
 measurement of normal levels (Letter) 235
 replacement, insulin resistance and vascular disease in men (Review) 239
 supplementation in postmenopausal women 32
- Thyroid carcinoma
 differentiated, in acromegaly 161
 differentiated, distant metastases and prognostic factors 87
 differentiated, prognostic factors and effect of therapy 418
 familial nonmedullary, and T1799A BRAF mutation 263
 medullary, and ghrelin 437
 medullary, and unique MEN type 2A phenotype 675
 papillary, BRAF^{V600E} mutation 461, 588
 papillary, incidental and non-incidental 577
 papillary, microcarcinomas 577, 588
- Thyroidectomy
 prophylactic, in MEN 2A kindreds 635
- Thyroid function
 ambulatory blood pressure monitoring 66
 blood flow in Graves' disease 656
 evaluation of iodine deficiency status 543
 TPOAb and T-lymphocyte cytokines 191
 in Williams syndrome 456
- Thyroiditis, Hashimoto's 191
- Thyroid nodules
 nonpalpable, management 688
- Thyroid register
 management of hypothyroidism (Letter) 116
- Thyroxine replacement
 hypothyroidism and cardiovascular risk 203
 maternal hypothyroidism in gestation 560
- T-Lymphocyte cytokines
 in Hashimoto's thyroiditis 191

- TNF- α
 - in diabetic neuropathy 525
- TPO autoantibodies
 - in Hashimoto's thyroiditis 191
- TSH
 - maternal hypothyroidism in gestation 560
 - receptor gene mutations and resistance 146
- Tuberous sclerosis
 - with Cushing's disease (Letter) 693
- Urine
 - analysis of iodine excretion 543
- Vascular growth factors
 - effects of GH status 79
- Vasopressin receptors
 - in familial ACTH-independent macronodular adrenal hyperplasia 624
- Vitamin D
 - in regulation of bone turnover in men (Review) 608
 - status in primary hyperparathyroidism 506
- Williams syndrome
 - thyroid function and morphology 456
- Women
 - clinical follow-up of hyperprolactinaemia 450
 - dermolipectomy, insulin action and inflammatory markers 253, (Commentary) 251
 - hypothyroidism in early and late gestation 560
 - infertility, assay for anti-Müllerian hormone 267
 - long-term somatostatin analogue therapy 342
 - oestrogens and cognition in the elderly 50
 - ovulation induction in PCOS 630
 - postmenopausal, testosterone supplementation 32
 - regulation of body composition 329
 - sex hormones, mobility and muscle strength in the elderly 152
 - subclinical hypothyroidism with diabetes mellitus type 2 (Letter) 479
 - type 2 diabetes, statins and chylomicron remnant catabolism 649
- Xanthoma disseminatum
 - with hypopituitarism (Letter) 119